Viking Global Investors LP and related entities filed a Schedule 13G with the SEC on November 20, 2026, disclosing beneficial ownership of shares of BioMarin Pharmaceutical Inc. common stock as of a triggering event dated November 13, 2026.

Key Highlights

  • Lead reporting person: Viking Global Investors LP, organized in Delaware, reported aggregate beneficial ownership of 9,356,178 shares, representing 4.8% of BioMarin Pharmaceutical Inc. common stock.
  • Shared power only: All reporting persons disclosed 0 sole voting power and 0 sole dispositive power; all 9,356,178 shares at the top level are held with shared voting and shared dispositive power.
  • Key individuals named: Ole Andreas Halvorsen (Norway) and Rose Sharon Shabet (United States) each reported shared beneficial ownership of 9,356,178 shares, or 4.8% of the class.
  • Viking Global Performance LLC separately reported 5,830,189 shares with shared voting and dispositive power, representing 3% of the class.
  • Viking Global Equities Master Ltd. (Cayman Islands) reported 5,713,586 shares, or 2.9% of the class, with shared voting and dispositive power.
  • Triggering event date: November 13, 2026, as stated in the filing.
  • Security covered: BioMarin Pharmaceutical Inc. common stock, par value $0.001 per share, CUSIP 09061G101.

Viking Global Entities Disclose Layered Ownership Structure in BioMarin

According to the Schedule 13G filing, eleven reporting persons affiliated with Viking Global collectively disclosed positions in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) common stock. The filing identifies the triggering event date as November 13, 2026. Viking Global Investors LP, as the top-level reporting entity, reported aggregate beneficial ownership of 9,356,178 shares, equal to 4.8% of the outstanding class. Both Ole Andreas Halvorsen and Rose Sharon Shabet, listed as individuals and reporting persons, each reported the same aggregate figure of 9,356,178 shares at 4.8%.

At the fund level, the filing discloses that Viking Global Performance LLC holds shared voting and dispositive power over 5,830,189 shares, or 3% of the class. Viking Global Equities Master Ltd., organized in the Cayman Islands, reported 5,713,586 shares representing 2.9%. Viking Long Fund Master Ltd. and Viking Long Fund GP LLC each reported 2,389,101 shares, or 1.2%. Viking Global Opportunities Liquid Portfolio Sub-Master LP and three related GP entities each reported 1,136,888 shares, or 0.6%. Viking Global Equities II LP reported 116,603 shares, or 0.1% of the class.

The filing notes that no reporting person holds any sole voting or sole dispositive power over any shares; all power is reported as shared in each case. The Schedule 13G was filed under Rule 13d-1(b), 13d-1(c), or 13d-1(d) as indicated on the cover, and each reporting person's type is noted as either PN (partnership), OO (other), CO (corporation), or IN (individual), with comments directing readers to Item 4 for further classification detail. BioMarin Pharmaceutical Inc.'s principal executive offices are listed at 770 Lindaro Street, San Rafael, California 94901.

What Was Disclosed

Eleven Viking Global-affiliated entities and individuals filed a Schedule 13G disclosing aggregate beneficial ownership of 9,356,178 shares of BioMarin Pharmaceutical Inc. common stock, representing 4.8% of the class, with all power held on a shared basis as of November 13, 2026.